Spyre Therapeutics, Inc. (SYRE) Misses Q1 EPS by 7c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q1 EPS of ($0.74), $0.07 worse than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• UBS Assumes Interactive Brokers Group (IBKR) at Neutral, 'A Best-in-Class, Yet Fairly Valued Brokerage'
• Goldman Sachs on Kingsoft Cloud (KC): 'AI cloud to drive revenue expansion with attractive investment payback'
• Mizuho: 'we believe CMG's cycle of lower margin revisions remains in the rear-view mirror'